ELI LILLY AND COMPANY Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $79.90 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-10-30.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2024-10-30
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-09-30 was $79.90M.
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-06-30 was -$103.70M.
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2024-03-31 was -$5.40M, a 107.03% decline year-over-year.
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2023-09-30 was -$12.10M.
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for fiscal 2022 was $247.70M, a 86.20% decline from fiscal 2021.
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was $1.80B.
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for fiscal 2020 was -$256.20M.
- ELI LILLY AND COMPANY other comprehensive income (loss), before reclassifications, net of tax for fiscal 2019 was -$997.60M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $79.90M 10-Q · filed 2024-10-30 | -$23.80M derived: sum of 2 quarters · filed 2024-10-30 | -$29.20M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | -$103.70M 10-Q · filed 2024-08-08 | -$109.10M 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | -$5.40M 10-Q · filed 2024-04-30 | |||
| 2023-09-30 | -$12.10M 10-Q · filed 2024-10-30 | -$38.80M derived: sum of 2 quarters · filed 2024-10-30 | $38.00M 10-Q · filed 2024-10-30 | $430.80M derived: sum of 4 quarters · filed 2024-10-30 |
| 2023-06-30 | -$26.70M 10-Q · filed 2024-08-08 | $50.10M 10-Q · filed 2024-08-08 | $442.90M derived: sum of 3 quarters · filed 2024-08-08 | $363.70M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $76.80M 10-Q · filed 2024-04-30 | $469.60M derived: sum of 2 quarters · filed 2024-04-30 | $390.40M derived: sum of 3 quarters · filed 2024-04-30 | $268.00M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | $392.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $313.60M derived: sum of 2 quarters · filed 2023-11-02 | $191.20M derived: sum of 3 quarters · filed 2023-11-02 | $247.70M 10-K · filed 2023-02-22 |
| 2022-09-30 | -$79.20M 10-Q · filed 2023-11-02 | -$201.60M derived: sum of 2 quarters · filed 2023-11-02 | -$145.10M 10-Q · filed 2023-11-02 | $1.60B derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$122.40M 10-Q · filed 2023-08-08 | -$65.90M 10-Q · filed 2023-08-08 | $1.68B derived: sum of 3 quarters · filed 2023-08-08 | $1.70B derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $56.50M 10-Q · filed 2023-04-27 | $1.80B derived: sum of 2 quarters · filed 2023-04-27 | $1.82B derived: sum of 3 quarters · filed 2023-04-27 | $1.84B derived: sum of 4 quarters · filed 2023-04-27 |
| 2021-12-31 | $1.74B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.77B derived: sum of 2 quarters · filed 2023-02-22 | $1.78B derived: sum of 3 quarters · filed 2023-02-22 | $1.80B 10-K · filed 2023-02-22 |
| 2021-09-30 | $25.00M 10-Q · filed 2022-11-01 | $43.40M derived: sum of 2 quarters · filed 2022-11-01 | $54.50M 10-Q · filed 2022-11-01 | $32.60M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $18.40M 10-Q · filed 2022-08-04 | $29.50M 10-Q · filed 2022-08-04 | $7.60M derived: sum of 3 quarters · filed 2023-02-22 | $102.00M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $11.10M 10-Q · filed 2022-04-29 | -$10.80M derived: sum of 2 quarters · filed 2023-02-22 | $83.60M derived: sum of 3 quarters · filed 2023-02-22 | $197.70M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | -$21.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $72.50M derived: sum of 2 quarters · filed 2023-02-22 | $186.60M derived: sum of 3 quarters · filed 2023-02-22 | -$256.20M 10-K · filed 2023-02-22 |
| 2020-09-30 | $94.40M 10-Q · filed 2021-10-27 | $208.50M derived: sum of 2 quarters · filed 2021-10-27 | -$234.30M 10-Q · filed 2021-10-27 | -$1.01B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $114.10M 10-Q · filed 2021-08-03 | -$328.70M 10-Q · filed 2021-08-03 | -$1.10B derived: sum of 3 quarters · filed 2022-02-23 | -$1.28B derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | -$442.80M 10-Q · filed 2021-04-30 | -$1.21B derived: sum of 2 quarters · filed 2022-02-23 | -$1.40B derived: sum of 3 quarters · filed 2022-02-23 | -$1.36B derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | -$772.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$954.00M derived: sum of 2 quarters · filed 2022-02-23 | -$916.90M derived: sum of 3 quarters · filed 2022-02-23 | -$997.60M 10-K · filed 2022-02-23 |
| 2019-09-30 | -$181.90M 10-Q · filed 2020-10-28 | -$144.80M derived: sum of 2 quarters · filed 2020-10-28 | -$225.50M 10-Q · filed 2020-10-28 | -$566.90M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-06-30 | $37.10M 10-Q · filed 2020-07-31 | -$43.60M 10-Q · filed 2020-07-31 | -$385.00M derived: sum of 3 quarters · filed 2021-02-17 | $225.30M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-03-31 | -$80.70M 10-Q · filed 2020-05-01 | -$422.10M derived: sum of 2 quarters · filed 2021-02-17 | $188.20M derived: sum of 3 quarters · filed 2021-02-17 | -$512.20M derived: sum of 4 quarters · filed 2021-02-17 |
| 2018-12-31 | -$341.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $268.90M derived: sum of 2 quarters · filed 2021-02-17 | -$431.50M derived: sum of 3 quarters · filed 2021-02-17 | -$106.90M 10-K · filed 2021-02-17 |
| 2018-09-30 | $610.30M 10-Q · filed 2019-10-25 | -$90.10M derived: sum of 2 quarters · filed 2019-10-25 | $234.50M 10-Q · filed 2019-10-25 | -$239.90M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | -$700.40M 10-Q · filed 2019-08-02 | -$375.80M 10-Q · filed 2019-08-02 | -$850.20M derived: sum of 3 quarters · filed 2020-02-19 | -$709.20M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $324.60M 10-Q · filed 2019-05-02 | -$149.80M derived: sum of 2 quarters · filed 2020-02-19 | -$8.80M derived: sum of 3 quarters · filed 2020-02-19 | $248.70M derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | -$474.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | -$333.40M derived: sum of 2 quarters · filed 2020-02-19 | -$75.90M derived: sum of 3 quarters · filed 2020-02-19 | $114.00M 10-K · filed 2020-02-19 |
| 2017-09-30 | $141.00M 10-Q · filed 2018-11-06 | $398.50M derived: sum of 2 quarters · filed 2018-11-06 | $588.40M 10-Q · filed 2018-11-06 | -$424.80M derived: sum of 4 quarters · filed 2019-10-24 |
| 2017-06-30 | $257.50M 10-Q · filed 2018-07-25 | $447.40M 10-Q · filed 2018-07-25 | -$565.80M derived: sum of 3 quarters · filed 2019-10-24 | -$492.40M derived: sum of 4 quarters · filed 2019-10-24 |
| 2017-03-31 | $189.90M 10-Q · filed 2018-04-27 | -$823.30M derived: sum of 2 quarters · filed 2019-10-24 | -$749.90M derived: sum of 3 quarters · filed 2019-10-24 | -$906.30M derived: sum of 4 quarters · filed 2019-10-24 |
| 2016-12-31 | -$1.01B derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | -$939.80M derived: sum of 2 quarters · filed 2019-10-24 | -$1.10B derived: sum of 3 quarters · filed 2019-10-24 | -$895.80M 8-K · filed 2019-10-24 |
| 2016-09-30 | $73.40M 10-Q · filed 2017-10-27 | -$83.00M derived: sum of 2 quarters · filed 2017-10-27 | $117.40M 10-Q · filed 2017-10-27 | $125.40M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | -$156.40M 10-Q · filed 2017-07-28 | $44.00M 10-Q · filed 2017-07-28 | $52.00M derived: sum of 3 quarters · filed 2018-02-20 | -$174.70M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | $200.40M 10-Q · filed 2016-04-29 | $208.40M derived: sum of 2 quarters · filed 2018-02-20 | -$18.30M derived: sum of 3 quarters · filed 2018-02-20 | $205.20M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | -$218.70M derived: sum of 2 quarters · filed 2018-02-20 | $4.80M derived: sum of 3 quarters · filed 2018-02-20 | -$705.10M 10-K · filed 2018-02-20 |
| 2015-09-30 | -$226.70M 10-Q · filed 2016-10-28 | -$3.20M derived: sum of 2 quarters · filed 2016-10-28 | -$713.10M 10-Q · filed 2016-10-28 | |
| 2015-06-30 | $223.50M 10-Q · filed 2016-07-28 | -$486.40M 10-Q · filed 2016-07-28 | ||
| 2015-03-31 | -$709.90M 10-Q · filed 2016-04-29 | |||
| 2014-09-30 | -$616.10M 10-Q · filed 2015-10-30 | -$613.90M derived: sum of 2 quarters · filed 2015-10-30 | -$590.30M 10-Q · filed 2015-10-30 | |
| 2014-06-30 | $2.20M 10-Q · filed 2015-07-30 | $25.80M 10-Q · filed 2015-07-30 | ||
| 2014-03-31 | $23.60M 10-Q · filed 2015-04-30 | |||
| 2013-09-30 | $302.30M 10-Q · filed 2014-10-29 | $290.90M derived: sum of 2 quarters · filed 2014-10-29 | -$700.00K 10-Q · filed 2014-10-29 | |
| 2013-06-30 | -$11.40M 10-Q · filed 2014-07-28 | -$303.00M 10-Q · filed 2014-07-28 | ||
| 2013-03-31 | -$291.60M 10-Q · filed 2014-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |